This court case has been in the news of late and now with the current ruling, it adds on one more layer of responsibility to the Name Brand drug company, in other words when the generic versions come out and are prescribed, they can piggyback the exact same warnings, thus the name brand company is now...
Posted to
The Medical Quack .... by Barbara Duck
on 11-18-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Pharma, Heatlhcare, Side Effects, Warnings, Lawsuits, liability, Generice drugs, drugs. name band drugs
I will once more mention a potential change of paradigms here with educating the public. Each patient who took the drug is unique. Do we have any information on other drugs they were taking at the same time? Groups will continue to advise against the use until the full facts are known...
Posted to
The Medical Quack .... by Barbara Duck
on 10-31-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, healthcare, Pharma, PHR, FDA, Marketing, paradigms, personal heatlh records
The bar has also risen on Venture Capital money and is harder to get, and so much of the research is still in the “Science” stage, there have been a few companies that have had failed products and just folded up and went away. This certainly leaves the door open for Pharma, who has the financials...
Posted to
The Medical Quack .... by Barbara Duck
on 10-29-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, Pharma, Biotech, Science, R and D, Venture Capitalists
I wonder if all the name brand companies will one day have nothing but generics? (grin). There’s always this interesting topic too, biosimilars. “Because biosimilars aren't exact duplicates of the original drugs, they don't violate the original drug's patent , enabling legal distribution...
Posted to
The Medical Quack .... by Barbara Duck
on 10-16-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, drugs, Pharma, Generic Drugs, Marketing, Pfizer, Biosimilars
Whistle blowers today seem to be playing a role in the move towards transparency in more ways than one, not to mention the bounty that could be there if a case goes to court and wrongdoing is found to be the case. BD A New Jersey arbitrator ruled that a former Amgen sales rep can proceed with a...
However, their prescription drug unit faced the same problems as the rest of the Pharma industry. A smart investment in consumer products is helping hold things together for J and J. The consumer product division was purchased from Pfizer in 2006, which was the company purchased by Pfizer...
Posted to
The Medical Quack .... by Barbara Duck
on 10-14-2008
Filed under: Medically Related, Pharma/FDA News, Other Items of Interest, personalized medicine, Genomics, Pharma, Pfizer, Phamaceuticals, Consumer Goods, J and J, Warner Lambert
As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
on 10-13-2008
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0